Canine lymphoma, as the most common hematopoietic malignancy, encompasses a group of heterogeneous diseases and even within the T-cell immunophenotype, differences in clinical presentation and responses to treatment exist. The aim of this retrospective study was to determine outcomes and prognostic factors of 107 dogs with multicentric non-indolent T-cell lymphoma receiving lomustine based (70%) and non-lomustine based (30%) treatment. The majority were Labradors, Boxers, mixed-breed dogs and Dogue de Bordeaux. Eighty-six percent were substage b, 77% had mediastinal involvement, 15% had suspected bone marrow involvement and 12% had other extra-nodal sites of disease. The overall response rate to induction therapy was 80%; dogs receiving procarbazine in the induction protocol (P = .042), dogs with neutrophil concentration below 8.7x10e9/L (P = 0.006) and mitotic rate below 10 per 5 hpf (P = 0.013), had greater response rates. Median progression-free survival (PFS) for the first remission was 105 days; lack of expression of CD3 on flow cytometry (P < 0.0001) and pretreatment with steroid (P = 0.012) were significantly associated with shorter PFS. Median overall survival (OST) was 136 days; co-expression of CD79a (P = 0.002), lack of CD3 expression on flow cytometry, presence of anemia (P = 0.007) and monocytopenia (P = 0.002) were predictive of shorter OST. Multicentric non-indolent T-cell lymphoma in dogs is an aggressive cancer with new possible prognostic factors. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.